Cargando…
Long‐term safety and efficacy of a novel once‐weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52‐week open‐label, phase 3 study
AIMS/INTRODUCTION: Trelagliptin is a novel once‐weekly oral dipeptidyl peptidase‐4 inhibitor for type 2 diabetes mellitus that was first approved in Japan. We evaluated long‐term safety and efficacy of trelagliptin in Japanese patients with type 2 diabetes mellitus. MATERIALS AND METHODS: This was a...
Autores principales: | Inagaki, Nobuya, Sano, Hiroki, Seki, Yoshifumi, Kuroda, Shingo, Kaku, Kohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5009134/ https://www.ncbi.nlm.nih.gov/pubmed/27181699 http://dx.doi.org/10.1111/jdi.12499 |
Ejemplares similares
-
Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study
por: Inagaki, Nobuya, et al.
Publicado: (2017) -
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial
por: Dubourg, Julie, et al.
Publicado: (2021) -
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
por: Kaku, Kohei, et al.
Publicado: (2018) -
Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study
por: Kaku, Kohei, et al.
Publicado: (2018) -
Effect of once weekly oral levothyroxine therapy
por: del Toro-Diez, Andrea, et al.
Publicado: (2021)